← Human Trials & Peer-Reviewed Studies
Acute parathyroid hormone increase by oral peptones administration after roux-en-Y gastric bypass surgery in obese subjects: role of phosphate in the rapid control of parathyroid hormone release
Plain-language guide to PMID 20403518 (2010): clinical trial study of Parathyroid Hormone (PTH 1-84) in 12 patients.
Key Facts
- PMID
- 20403518
- Journal
- Surgery
- Year
- 2010
- Study type
- Clinical Trial
- Authors
- Bevilacqua M et al. (12 authors)
- DOI
- 10.1016/j.surg.2009.08.011
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) in this clinical trial publication.
It is generally considered that changes in serum phosphate levels do not alter parathyroid hormone (PTH) secretion in the absence of concomitant changes in ionized serum calcium level in humans.
The researchers aimed to study gastrin, phosphate, PTH, ionized calcium (iCa), and blood pH responses to oral peptones in morbidly obese patients before and after roux-en-Y gastric bypass (RYGB) surgery.
Who Took Part
The study group was 12 patients.
By PubMed's age tags, the people studied were young adults and adults, both men and women.
These parameters were evaluated in response to an oral peptone load in 24 (18 male and 6 female) obese subjects before and 6 months after RYGB surgery.
In 12 gastric bypass patients, the researchers also evaluated PTH and phosphate after peptones plus aluminum hydroxide administration to suppress phosphate absorption.
What Was Measured
It is generally considered that changes in serum phosphate levels do not alter parathyroid hormone (PTH) secretion in the absence of concomitant changes in ionized serum calcium level in humans.
The subject headings attached to it are Aluminum Hydroxide, Calcium, Gastric Bypass, Gastrins, Hydrogen-Ion Concentration, Intestinal Absorption and Jejunum.
What This Means in Plain Language
This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 12 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2010 (Surgery), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.